Current Report Filing (8-k)
January 19 2018 - 2:46PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_____________________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (date of earliest event reported): January 19, 2018
_____________________
TONIX
PHARMACEUTICALS HOLDING CORP.
(Exact
name of registrant as specified in its charter)
Nevada
|
001-36019
|
26-1434750
|
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
509
Madison Avenue, Suite 306, New York, New York 10022
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code:
(212) 980-9155
Copy
of correspondence to:
Michael
J. Lerner, Esq.
Lowenstein
Sandler LLP
One
Lowenstein Drive
Roseland,
NJ 07068
Tel:
(973) 597-2500 Fax: (973) 597-6395
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☐
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item
8.01 Other Events.
On
January 19, 2018, the Company issued a press release announcing a publication reporting the synthesis, construction and characterization
of a potential smallpox-preventing vaccine candidate TNX-801. A copy of the press release is filed as Exhibit 99.01 hereto and
incorporated herein by reference.
The
information in this Current Report, including exhibits, is being furnished and shall not be deemed “filed” for
the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The
information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant
to the Securities Act of 1933, except as shall be expressly set forth by specific reference in any such filing, and is not deemed
an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation
FD.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits.
______
*
Furnished herewith.
SIGNATURE
Pursuant
to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
TONIX PHARMACEUTICALS HOLDING
CORP.
|
|
|
Date: January
19, 2018
|
By:
|
/s/
Bradley Saenger
|
|
|
Bradley
Saenger
Chief Financial Officer
|
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Apr 2023 to Apr 2024